Re: Farmas USA
AMRN
Amarin Hampered By Rising Operational Costs But Could Be Saved By First Amendment
Hasta los analistas se encomiendan ya a la 1a enmienda... Y tambien explica (más bien especula) como se ha contabilizado el tema de los 15 mill. Nada de Q3. Amortización a 10 años y 375.000$ por trimestre:
The $15.0 million up-front licensing fee received from Eddingpharm in February seems to have been amortized over 10 years and will only be contributing $375,000 per quarter to revenues.